Status In progress
Process STA
ID number 931

Provisional Schedule

Final appraisal determination 10 July 2017 - 24 July 2017
Expected publication 09 August 2017

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Ipsen (cabozantinib)
Others Department of Health
  NHS Dudley CCG
  NHS England
  NHS Wandsworth CCG
  Welsh Government
Patient carer groups Kidney Cancer Support Network
  Kidney Cancer UK
Professional groups Association of Cancer Physicians
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians


Associated public health groups None
Comparator companies Pfizer (axitinib)
  Bristol-Myers Squibb (nivolumab)
  Novartis (everolimus)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
23 May 2017 Committee meeting: 3
19 April 2017 - 11 May 2017 Appraisal consultation: 2
23 March 2017 Committee meeting: 2
21 February 2017 - 14 March 2017 Appraisal consultation
25 January 2017 Committee meeting: 1
15 August 2016 Invitation to participate
01 July 2016 Draft scope documents
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance